This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Bioequivalency Remove In-Vivo Remove Pharma Companies Related Topics
Generic Drugs Big Data In-Vitro Genomics Genome Clinical Trials Containment Licensing FDA Approval Medicine More Related Topics >
article thumbnail

In the News: October Regulatory and Development Updates

Camargo

NOVEMBER 11, 2020

In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, the U.S.

Development 242
Development Bioequivalency Generic Drugs Production 242
article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

AUGUST 22, 2023

Originator pharma companies are developing ever more complex products, which are transforming the medical landscape, but their cost places an increasing burden on healthcare budgets worldwide. In the meantime, the absence of generics is costing payors and patients billions of dollars in unnecessary additional healthcare expenditure.

Production 52
Production Bioequivalency In-Vivo In-Vitro 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024